Abstract
Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have